Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 15/20 | 0.96 |
| ▸ | NPC1 | O15118 | 4/20 | 0.54 |
| ▸ | RAB9A | P51151 | 4/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.54 |
| ▸ | MEN1 | O00255 | 3/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | LMNA | P02545 | 2/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.52 |
| ▸ | TSHR | P16473 | 1/20 | 0.52 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4883194 | 0.98 | DGAT1 (1.00) | DGAT1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL4920050 | 0.89 | DGAT1 (0.84) | DGAT1KMT2AMEN1 | |
| SCHEMBL4883628 | 0.88 | DGAT1 (0.76) | DGAT1NPC1RAB9AKMT2AMEN1 | |
| SCHEMBL4921498 | 0.86 | DGAT1 (0.78) | DGAT1 | |
| SCHEMBL4886387 | 0.86 | DGAT1 (0.81) | DGAT1RAB9ALMNAHTT | |
| SCHEMBL2742723 | 0.86 | DGAT1 (1.00) | DGAT1RAB9AMAPTLMNA | |
| SCHEMBL5372960 | 0.86 | DGAT1 (1.00) | DGAT1RAB9AMAPTLMNA | |
| SCHEMBL21995882 | 0.86 | DGAT1 (1.00) | DGAT1RAB9AMAPTLMNA | |
| SCHEMBL4920372 | 0.85 | DGAT1 (0.76) | DGAT1 | |
| SCHEMBL4892114 | 0.84 | DGAT1 (1.00) | DGAT1NPC1RAB9AKMT2AMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080015227-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | claimed |
| US-20080015227-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | ABBOTT LABORATORIES | 2008-01-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015227-A1 | Inhibitors of diacylglycerol O-acyltransferase type 1 enzyme | DGAT1, DGAT2, LCAT | DGAT1 1/4885NPC1 107/4885RAB9A 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.